Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis

I. Tsuboi, A. Matsukawa, MK. Parizi, M. Miszczyk, T. Fazekas, RJ. Schulz, E. Laukhtina, T. Kawada, S. Katayama, T. Iwata, K. Bekku, P. Rajwa, K. Wada, K. Oberneder, P. Chlosta, PI. Karakiewicz, M. Araki, SF. Shariat

. 2025 ; 25 (1) : 107. [pub] 20250428

Language English Country England, Great Britain

Document type Journal Article, Systematic Review, Meta-Analysis

Persistent link   https://www.medvik.cz/link/bmc25016027

BACKGROUND: Immune checkpoint inhibitors (ICI) and chemotherapy, including antibody-drug conjugates, are widely used for the treatment of patients with advanced unresectable or metastatic urothelial carcinoma (UC). The majority of elderly patients receive concomitant medications to address various comorbidities. We aimed to evaluate the impact of concomitant medications on oncological outcomes in patients with advanced unresectable or metastatic UC treated with systemic therapy. MATERIAL & METHODS: In August 2024, three datasets were queried for studies evaluating concomitant medications in patients with advanced unresectable or metastatic UC. The review protocol was registered in PROSPERO (CRD42024547335). The primary outcome was overall survival (OS). A fixed- or random-effects model was used for meta-analysis depending on the heterogeneity. RESULTS: We identified 16 eligible studies (3 prospective and 13 retrospective) comprising 4,816 patients. Most reported concomitant medications included proton pump inhibitors (PPIs), antibiotics, steroids, and opioids. The use of concomitant PPIs, antibiotics, steroids or opioids during ICI therapy was associated with worsened OS (PPIs: HR: 1.43, 95% CI: 1.31-1.57, p < 0.001; antibiotics: HR: 1.2, 95% CI: 1.04-1.38, p = 0.01; steroids: HR: 1.45, 95% CI: 1.25-1.67, p < 0.001; and opioids: HR: 1.74, 95% CI: 1.46-2.07, p < 0.001). Concomitant use of antibiotics during chemotherapy did not impact OS (HR: 1.01, 95% CI: 0.67-1.51). CONCLUSIONS: When treating advanced unresectable or metastatic UC with ICI therapy, we need to pay attention to concomitant medications, such as PPIs and antibiotics to avoid reducing the efficacy of ICI therapy. The mechanism of action of these drugs on ICI efficacy requires further examination.

2nd Department of Urology Centre of Postgraduate Medical Education Warsaw Poland

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal QC Canada

Collegium Medicum Faculty of Medicine WSB University Dąbrowa Górnicza Poland

Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia Czechia

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Dentistry and Pharmaceutical Sciences Okayama University Graduate School of Medicine Okayama Japan

Department of Urology Jikei University School of Medicine Tokyo Japan

Department of Urology Medical College Jagiellonian University Krakow Poland

Department of Urology Semmelweis University Budapest Hungary

Department of Urology Shariati Hospital Tehran University of Medical Sciences Tehran Iran

Department of Urology Shimane University Faculty of Medicine Shimane Japan

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Research Center for Evidence Medicine Urology Department Tabriz University of Medical Sciences Tabriz Iran

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016027
003      
CZ-PrNML
005      
20250731091440.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12894-025-01754-2 $2 doi
035    __
$a (PubMed)40296069
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tsuboi, Ichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
245    10
$a Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis / $c I. Tsuboi, A. Matsukawa, MK. Parizi, M. Miszczyk, T. Fazekas, RJ. Schulz, E. Laukhtina, T. Kawada, S. Katayama, T. Iwata, K. Bekku, P. Rajwa, K. Wada, K. Oberneder, P. Chlosta, PI. Karakiewicz, M. Araki, SF. Shariat
520    9_
$a BACKGROUND: Immune checkpoint inhibitors (ICI) and chemotherapy, including antibody-drug conjugates, are widely used for the treatment of patients with advanced unresectable or metastatic urothelial carcinoma (UC). The majority of elderly patients receive concomitant medications to address various comorbidities. We aimed to evaluate the impact of concomitant medications on oncological outcomes in patients with advanced unresectable or metastatic UC treated with systemic therapy. MATERIAL & METHODS: In August 2024, three datasets were queried for studies evaluating concomitant medications in patients with advanced unresectable or metastatic UC. The review protocol was registered in PROSPERO (CRD42024547335). The primary outcome was overall survival (OS). A fixed- or random-effects model was used for meta-analysis depending on the heterogeneity. RESULTS: We identified 16 eligible studies (3 prospective and 13 retrospective) comprising 4,816 patients. Most reported concomitant medications included proton pump inhibitors (PPIs), antibiotics, steroids, and opioids. The use of concomitant PPIs, antibiotics, steroids or opioids during ICI therapy was associated with worsened OS (PPIs: HR: 1.43, 95% CI: 1.31-1.57, p < 0.001; antibiotics: HR: 1.2, 95% CI: 1.04-1.38, p = 0.01; steroids: HR: 1.45, 95% CI: 1.25-1.67, p < 0.001; and opioids: HR: 1.74, 95% CI: 1.46-2.07, p < 0.001). Concomitant use of antibiotics during chemotherapy did not impact OS (HR: 1.01, 95% CI: 0.67-1.51). CONCLUSIONS: When treating advanced unresectable or metastatic UC with ICI therapy, we need to pay attention to concomitant medications, such as PPIs and antibiotics to avoid reducing the efficacy of ICI therapy. The mechanism of action of these drugs on ICI efficacy requires further examination.
650    _2
$a lidé $7 D006801
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    12
$a karcinom z přechodných buněk $x diagnóza $x farmakoterapie $x mortalita $x sekundární $7 D002295
650    12
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a výsledek terapie $7 D016896
650    12
$a urologické nádory $x diagnóza $x farmakoterapie $x mortalita $x patologie $7 D014571
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
655    _2
$a metaanalýza $7 D017418
700    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Parizi, Mehdi Kardoust $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
700    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
700    1_
$a Fazekas, Tamás $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Schulz, Robert J $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Iwata, Takehiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland
700    1_
$a Wada, Koichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
700    1_
$a Oberneder, Katharina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Chlosta, Piotr $u Department of Urology, Medical College, Jagiellonian University, Krakow, Poland
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada
700    1_
$a Araki, Motoo $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Semmelweis University, Budapest, Hungary. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia, Czechia. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00008208 $t BMC urology $x 1471-2490 $g Roč. 25, č. 1 (2025), s. 107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40296069 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091435 $b ABA008
999    __
$a ok $b bmc $g 2366701 $s 1253152
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 1 $d 107 $e 20250428 $i 1471-2490 $m BMC urology $n BMC Urol $x MED00008208
LZP    __
$a Pubmed-20250708
Back

Find record

Citation metrics

Archiving options